Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches.
Diamantopoulos PT, Viniou NA.
Front Oncol. 2021 Nov 17;11:722507. doi: 10.3389/fonc.2021.722507. eCollection 2021.
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH Jr, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW.
J Clin Oncol. 2020 Apr 1;38(10):1006-1018. doi: 10.1200/JCO.19.00895. Epub 2019 Dec 27.
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM, Lasho T.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):460-464. doi: 10.1182/hematology.2020000163.
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH.
J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1.
Atypical Presentation of Chronic Myelogenous Leukemia.
Updyke KM, Morales-Lappot J, Lee T.
Cureus. 2017 May 26;9(5):e1280. doi: 10.7759/cureus.1280.
Myelodysplastic/myeloproliferative neoplasms.
Cazzola M, Malcovati L, Invernizzi R.
Hematology Am Soc Hematol Educ Program. 2011;2011:264-72. doi: 10.1182/asheducation-2011.1.264.
Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms.
Sadigh S, Hasserjian RP, Hobbs G.
Curr Opin Hematol. 2020 Mar;27(2):122-127. doi: 10.1097/MOH.0000000000000565.
Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
Kim SY, Song IC, Kim J, Kwon GC.
Ann Diagn Pathol. 2024 Aug;71:152317. doi: 10.1016/j.anndiagpath.2024.152317. Epub 2024 Apr 18.
RNF6 promotes chronic myelogenous leukemia cell proliferation and migration by stabilizing vimentin via multiple atypical ubiquitinations.
Zhang H, Zhong Y, He Y, Xu Y, Ren Y, Zhuang H, Sun T, Zhu Z, Mao X.
Genes Dis. 2023 May 10;11(1):87-90. doi: 10.1016/j.gendis.2023.04.004. eCollection 2024 Jan.
Stem cells in chronic myelogenous leukemia.
Verfaillie CM.
Hematol Oncol Clin North Am. 1997 Dec;11(6):1079-114. doi: 10.1016/s0889-8588(05)70484-6.
